SAN DIEGO — Revolution Medicines is advancing the next generation of RAS-inhibiting drugs, with promising clinical and preclinical data presented at the American Association for Cancer Research (AACR) 2024 annual meeting.
The company is gaining attention for the clinical success of daraxonrasib, its next-generation targeted therapy, in treating advanced pancreatic cancer. On Tuesday, Revolution Medicines shared updated trial results, highlighting encouraging first-line and combination therapy data for daraxonrasib.
In a separate session, scientists unveiled preclinical data on a new compound, RM-055, which may represent the future of RAS-targeting treatments. Revolution Medicines CEO Mark Goldsmith described RM-055 as an entirely “novel class of catalytic inhibitors.” Unlike existing therapies, these inhibitors not only block RAS signaling—a key driver of cancer—but also molecularly deactivate the cancer protein.
Related articles
PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Why Major Digital Health Companies Are Absent from Medicare’s Chronic Care Pilot Program
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it deli...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
Kyle Diamantas Named Acting FDA Commissioner Amid Biotech Sector Optimism
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their...